Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy
- PMID: 18781673
- DOI: 10.1002/mds.22020
Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy
Abstract
Dopamine (DA) neurons exist in two activity states; either spontaneously firing or quiescent and nonfiring. When faced with a behavioral demand, the quiescent DA neurons can be activated to facilitate normal motor output. Levodopa appears to increase DA output by activating these nonfiring neurons; as a consequence, DA release is increased, but behavioral demand can now overwhelm the system, potentially leading to the inactivation and on/off phenomena. Levodopa administered in a pulsatile manner may also lead to the induction of synaptic plasticity within the DA systems. In the ventral mesolimbic system, this could lead to the loss of behavioral flexibility, impulsive behavior, and cognitive impairment, whereas in the dorsal nigrostriatal system, this may underlie Levodopa-induced dyskinesia. Continuous administration of Levodopa may circumvent this sensitization process, enabling a therapeutic response without limbic and motor side effects.
(c) 2008 Movement Disorder Society.
Similar articles
-
Synaptic dysfunction in Parkinson's disease.Biochem Soc Trans. 2010 Apr;38(2):493-7. doi: 10.1042/BST0380493. Biochem Soc Trans. 2010. PMID: 20298209 Review.
-
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2. Brain. 2009. PMID: 19050033
-
Myths and realities of continuous dopaminergic stimulation.Psychiatr Danub. 2011 Mar;23(1):80-3. Psychiatr Danub. 2011. PMID: 21448103 Review.
-
[Thoughts on the neurobiological aspects of Parkinson syndrome].Psychiatr Neurol Med Psychol (Leipz). 1986 Feb;38(2):86-90. Psychiatr Neurol Med Psychol (Leipz). 1986. PMID: 3010357 German.
-
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.Mov Disord. 2008;23 Suppl 3:S548-59. doi: 10.1002/mds.22062. Mov Disord. 2008. PMID: 18781672 Review.
Cited by
-
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5. CNS Drugs. 2016. PMID: 27344665 Review.
-
Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward.J Neurosci. 2011 Feb 9;31(6):2180-7. doi: 10.1523/JNEUROSCI.5540-10.2011. J Neurosci. 2011. PMID: 21307254 Free PMC article.
-
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease.NPJ Parkinsons Dis. 2023 Jun 24;9(1):98. doi: 10.1038/s41531-023-00541-w. NPJ Parkinsons Dis. 2023. PMID: 37355689 Free PMC article. Review.
-
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250. doi: 10.1007/s00702-018-1869-1. Epub 2018 Mar 7. J Neural Transm (Vienna). 2018. PMID: 29511826 Review.
-
Levodopa increases speed of alternating movements in Parkinson's disease patients.J Neural Transm (Vienna). 2013 Feb;120(2):309-13. doi: 10.1007/s00702-012-0848-1. Epub 2012 Jun 22. J Neural Transm (Vienna). 2013. PMID: 22722446
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical